Lomerizine — used clinically to treat migraines — helped ease vascular-related symptoms in a mouse model of Fabry disease,…
Andrea Lobo, PhD
Andrea Lobo holds a PhD in cell biology/neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She has authored multiple research papers in peer-reviewed journals.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo, PhD
A 10-year-old boy diagnosed with Fabry disease was also found to have a rare blood disorder called congenital dyserythropoietic…
Chiesi Global Rare Diseases is launching a research grant initiative to support innovative studies into Fabry disease, alpha-mannosidosis,…
Relay Therapeutics said it expects to start clinical development of its treatment candidate for Fabry disease in the…
Fabry disease, in rare instances, may be among the causes of aseptic meningitis, a condition in which there is…
A 69-year-old man diagnosed with Fabry disease who developed heart failure, high pulmonary arterial pressure, and heart microcirculation dysfunction…
A mutation in the GLA gene associated with Fabry disease was found by Italian researchers in a woman with end-stage…
Most children with Fabry disease, particularly those with the severe, classic form, have lower than normal skeletal muscle…
The duration and rate of Fabrazyme (agalsidase beta) infusion can be safely changed in people with Fabry disease,…
Chiesi Global Rare Diseases and Aliada Therapeutics are teaming up to advance a blood-brain barrier (BBB) crossing platform…